Cencora, Inc. (NYSE:COR) Shares Sold by Jump Financial LLC

Jump Financial LLC reduced its position in Cencora, Inc. (NYSE:COR - Free Report) by 96.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,341 shares of the company's stock after selling 83,228 shares during the quarter. Jump Financial LLC's holdings in Cencora were worth $751,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Aware Super Pty Ltd as trustee of Aware Super purchased a new stake in Cencora during the 4th quarter valued at approximately $3,756,000. XTX Topco Ltd grew its position in Cencora by 155.0% in the 4th quarter. XTX Topco Ltd now owns 5,899 shares of the company's stock valued at $1,325,000 after buying an additional 3,586 shares during the last quarter. Belpointe Asset Management LLC raised its position in Cencora by 13.8% during the 4th quarter. Belpointe Asset Management LLC now owns 3,997 shares of the company's stock worth $958,000 after buying an additional 484 shares during the last quarter. CreativeOne Wealth LLC lifted its stake in shares of Cencora by 6.0% in the 4th quarter. CreativeOne Wealth LLC now owns 5,708 shares of the company's stock worth $1,282,000 after acquiring an additional 322 shares during the period. Finally, Mariner LLC boosted its holdings in shares of Cencora by 3.6% in the fourth quarter. Mariner LLC now owns 56,412 shares of the company's stock valued at $12,675,000 after acquiring an additional 1,969 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total value of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares in the company, valued at $89,027,442.53. This trade represents a 4.41 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the sale, the executive vice president now owns 14,665 shares of the company's stock, valued at approximately $3,934,326.20. The trade was a 21.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,223 shares of company stock valued at $13,580,967. Insiders own 10.80% of the company's stock.

Cencora Price Performance

Cencora stock traded up $3.66 during midday trading on Friday, reaching $286.05. 1,815,757 shares of the company were exchanged, compared to its average volume of 1,520,659. The firm's 50-day simple moving average is $267.20 and its 200-day simple moving average is $248.71. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $296.65. The company has a market capitalization of $55.47 billion, a price-to-earnings ratio of 40.69, a P/E/G ratio of 1.31 and a beta of 0.55. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.77%. Cencora's payout ratio is currently 31.29%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. JPMorgan Chase & Co. increased their price objective on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Morgan Stanley set a $288.00 target price on shares of Cencora in a research report on Tuesday, April 15th. Finally, Bank of America boosted their price target on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and a consensus target price of $284.55.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.